NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
REDBevacizumab Avastin®
(25 mg/ml concentrate for solution for infusion. ) 		Malignant disease and immunosuppression, Bevacizumab, 08.01.05
REDBevacizumab gamma Lytenava®
(25 mg/mL solution for injection) 		Eye, Subfoveal choroidal neovascularisation, 11.08.02
REDBevacizumab intravitreal 1.25mg in 0.05mL Avastin®
(Injection) 		Eye, Subfoveal choroidal neovascularisation, 11.08.02
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local BNF Section
Bevacizumab Bevacizumab [Specialist Drug] Malignant Disease, Antibody Responsive Malignancy, Antineoplastic Drugs Monoclonal Antibodies
Selecting a button in the local column will search the local formulary again for the word on the button. Where the button is in outline no local match at drug name level was found.
Links found
MHRA Drug Safety Update (January 2011) - Bevacizumab and sunitinib: risk of osteonecrosis of the jaw
NICE TA1008: Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments
NICE TA1022: Bevacizumab gamma for treating wet age-related macular degeneration
NICE TA118: Colorectal cancer (metastatic) - bevacizumab & cetuximab
NICE TA212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
NICE TA214: Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer
NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
NICE TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma
NICE TA693: Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer
NICE TA885 Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (replaced by TA939)
NICE TA885: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (replaced by TA939)
NICE TA939: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
NICE TA946: Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer